Reversibility of Brain Glucose Transport and Metabolism in T2DM

Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control. The main question\[s\] it aims to answer are: * To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control. * Assess which factors, (duration of diabetes mellitus (DM) and glycemic control) contribute to changes in glucose transport Participants will have: * A screening visit * placement of a continuous glucose monitor (CGM) 2 weeks before the first magnetic resonance spectroscopy (MRS) at week 0 * Additional visits/phone calls for intensification of diabetes management and nutrition visits * Second magnetic resonance spectroscopy (MRS) at week 12

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 18-60

• medical history for Type 2 diabetes

• HbA1c \> 7.5%, BMI ≥18 kg/m2

• Be willing to adhere to the intensification of their diabetes regimen

Locations
United States
Connecticut
Yale New Haven Hospital (YNHH) Research Unit (HRU)
RECRUITING
New Haven
Contact Information
Primary
Elizabeth Sanchez Rangel, MD
elizabeth.sanchezrangel@yale.edu
203-785-6430
Time Frame
Start Date: 2024-07-19
Estimated Completion Date: 2027-05-31
Participants
Target number of participants: 24
Treatments
Other: Aim 1
Intervention before and after study with subjects with uncontrolled T2DM to measured brain glucose transport specifically in the occipital lobe during acute hyperglycemia
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: Yale University

This content was sourced from clinicaltrials.gov